Description
BI-695502 is an investigational drug currently being studied by Boehringer Ingelheim. It is being evaluated in clinical trials for the treatment of metastatic colorectal cancer. Specifically, a Phase 3 trial (NCT02776683) is investigating BI-695502 in combination with a standard chemotherapy regimen (mFOLFOX6, which includes leucovorin, 5-fluorouracil, and oxaliplatin) for patients who have not received prior treatment for their metastatic disease. The trial aims to assess the safety and effectiveness of this combination, looking at measures like progression-free survival (how long the cancer doesn't grow), objective response rate (how many patients see their tumors shrink), overall survival (how long patients live), duration of response, and time to progression.
Mechanism of Action
The specific way BI-695502 works (its mechanism of action) is not fully detailed in the available trial information. It is being studied in combination with standard chemotherapy (mFOLFOX6) to see if it can improve outcomes for patients with metastatic colorectal cancer. Further research is needed to fully understand its molecular target and how it interacts with cancer cells.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.